AbbVie outlines 2026 adjusted EPS of $13.95-$13.99 while raising expected revenue to $67.8B

Nigeria South Africa Ghana Senegal Uganda Kenya Morocco Egypt Zimbabwe Tanzania Algeria Ethiopia Sudan Ivory Coast Libya Somalia Tunisia Zambia Mozambique DR Congo Angola

India Malaysia Iran China South Korea Japan Israel United Arab Emirates Philippines Pakistan Saudi Arabia Indonesia Turkey Cambodia Singapore Thailand Vietnam North Korea Yemen Bangladesh Palestine Nepal Taiwan Kazakhstan Iraq Lebanon Syria Qatar Afghanistan Sri Lanka Jordan Kuwait Uzbekistan Laos

United Kingdom Russia Germany France Spain Italy Ukraine Portugal Ireland Austria Netherlands Poland Finland Romania Switzerland Greece Czech Republic Hungary Belgium Denmark Sweden Norway Serbia Croatia Georgia Bulgaria Belarus Slovakia Slovenia Iceland

United States Mexico Canada Dominican Republic Costa Rica Guatemala Puerto Rico Honduras Jamaica Cuba Panama Belize Nicaragua El Salvador Haiti Bahamas Trinidad and Tobago Barbados

Brazil Peru Colombia Argentina Ecuador Venezuela Bolivia Uruguay Chile Paraguay

Australia New Zealand Papua New Guinea Fiji